The influence of fractionated radiotherapy on the stability of spinal bone metastases: a retrospective analysis from 1047 cases

Table 1 Demographics

	<= 10 fractions		> 10 fractions		All patients		p-value
	n = 769		n = 278		n = 1047
	n	%	n	%	n	%
Age (years)
Mean (SD)	63.3 +/− 10.7		62.5 +/− 12.0		63.1 +/− 11.1		0.330^a
Gender
Male	435	56.6	143	51.4	578	55.2	0.141^b
Female	334	43.4	136	48.6	469	44.8
Karnofsky-index
Median (range)	80 (40–100)		80 (30–100)		80 (30–100)		0.696^c
Primary site							< 0.001^b
NSCLC	356	46.3	69	24.8	425	40.6
Breast cancer	106	13.8	69	24.8	175	16.7
Renal cancer	88	11.4	71	25.5	159	15.2
Other	219	28.5	69	24.8	288	27.5
Localization of metastases							0.476^b
Cervical	1	0.1	1	0.3	2	0.2
Thoracic	460	59.8	145	63.0	635	60.7
Lumbar	308	40.1	102	36.7	410	39.1
Number of metastases							0.329^b
Mean (SD)	2.6 +/− 2.1		2.9 +/− 2.8		2.7 +/− 2.3		0.069^a
Solitary	350	45.5	136	48.9	486	46.4
Multiple	419	54.5	142	51.1	561	53.6
Other distant metastases
Liver	203	26.4	60	21.6	263	25.1	0.112^b
Brain	112	14.6	30	10.8	142	13.6	0.119^b
Lung	185	24.1	74	26.6	259	24.7	0.396^b
Tissue	55	7.2	12	4.3	67	6.4	0.097^b
Antiresoptive treatment	513	66.7	142	51.1	655	62.6	< 0.001^b
Chemotherapy	445	57.9	145	52.4	590	56.4	0.112^b
Stable metastases	392	51.0	121	43.5	513	49.0	0.033^b
Unstable metastases	377	49.0	157	56.5	534	51.0
Orthopedic corset	353	45.9	122	43.9	475	45.4	0.562^b
Radiotherapy schedule
1 × 8 Gy					1	0.1
5 × 4 Gy					11	1.0
10 × 3 Gy					757	72.3
11 × 3 Gy					1	0.1
12 × 3 Gy					1	0.1
14 × 2.5 Gy					92	8.8
20 × 2 Gy					184	17.6

Baseline characteristics of participants. Explanation: Others: colon cancer, neuroendocrine cancer, prostata cancer, ovarian cancer, urothelial cancer, uterine cancer, vulva cancer. Abbreviation: NSCLC non-small-cell lung carcinoma; ^at-test; ^bchi-square-test, ^cu-test

ISSN: 1748-717X